跳至主要内容
临床试验/NCT06055309
NCT06055309已完成1 期

Behavioral Pharmacology of Cannabis in Older Adults: A Pilot Study

University of Arkansas1 个研究点 分布在 1 个国家目标入组 3 人开始时间: 2025年5月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
3
试验地点
1
主要终点
Self/Observer Ratings - POMS

研究概览

简要总结

This study examines the effects of cannabis on mood, cognitive and psychomotor performance, balance and vital signs in older adults.

详细描述

The overarching aims of this pilot study are to determine the dose-related effects of cannabis and explore feasibility and acceptability of conducting a rigorous behavioral pharmacology study in this population. Using a within-subject design in older adults (55-70 years), this study will (1) determine acute dose-related effects of cannabis on physiological, subjective, cognitive, and psychomotor measures and (2) explore acceptability/feasibility of this approach among older adults in order to refine procedures for future studies. Volunteers (55-70 years) will undergo three 7.5-hour experimental sessions conducted one week apart, in which they receive cannabis containing various oral doses of tetrahydrocannabinol (THC) / cannabidiol (CBD) administered in a brownie formulation and the following are assessed: 1) self-reported and/or observer ratings of positive and negative subjective effects; 2) performance effects, measured by reaction time, coordination, and cognitive impairment; and 3) cardiovascular effects. Participants will be contacted the day after each session for feedback on the acceptability of session length, types, number and duration of tasks and any adverse events. Reasons for dropout will also be sought to determine whether study procedures impacted attrition. Findings will: 1) provide investigative team with the hands-on research cannabis research experience; 2) elucidate the optimal THC dose range; and 3) determine the most feasible/acceptable study design in older adults that will inform further rigorous studies examining acute and chronic administration of cannabis formulations among older adults.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

盲法说明

brownies will contain different doses of cannabis product

入排标准

年龄范围
55 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Self-reported history of marijuana use with no serious adverse effects
  • Negative urine toxicology screen for psychoactive drugs (cocaine, fentanyl, methadone, opiates, buprenorphine, methamphetamine, amphetamines, barbiturates, oxycodone, benzodiazepines, phencyclidine, and THC) and CBD
  • Negative breath alcohol concentration
  • Report ≥1 year abstinence from nicotine and tobacco
  • Report ≥1 month of abstinence from THC- and CBD- containing products and be willing to abstain from these products for the study duration
  • Blood pressure (BP) reading ≤140/90 and ≥110/70 at the time of screening
  • Read and understand English (because assessments are validated in English)
  • Menopause as defined as no reported menstruation for ≥12 months (females only)
  • Negative urine pregnancy test (females only)
  • Stable medical conditions controlled by non-psychoactive medications that do not alter THC/CBD metabolism (e.g., hypertension under control with certain antihypertensives; type II diabetes controlled by metformin)

排除标准

  • A history of moderate to severe substance use disorders (SUDs) (except tobacco), according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), and no recent history (≥1 year) of SUD
  • Current tobacco/nicotine use
  • ECG abnormalities at screening including but not limited to: bradycardia (<55 beats per minute); prolonged QTc interval (>450 msec); Wolff-Parkinson White syndrome; wide complex tachycardia; 2nd degree, Mobitz type II heart block; 3rd degree heart block; left or right bundle branch block; pre-existing severe gastrointestinal narrowing (pathologic or iatrogenic)
  • Have a serious and uncontrolled medical condition (major cardiovascular, renal, endocrine, or hepatic disorder) including a history of serious head trauma or neurological disorder (e.g., seizure disorder)
  • Meet Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for lifetime psychosis, schizophrenia, or bipolar disorder or current major depressive disorder, suicidality (e.g., last month suicidal ideation or suicide attempt in past year, as measured by Columbia Suicide Severity Rating Scale) or have significant psychiatric symptoms of another disorder
  • Diagnosis of a cognitive disorder (Alzheimer's Disease, dementia) or a score of <25 on the Montreal Cognitive Assessment (MoCA) for Dementia during screening
  • Currently taking any prescribed medication for a psychiatric disorder
  • Current use of over-the-counter medication or prescription psychoactive drugs that would be expected to have major interaction with THC (e.g., warfarin, serotonin reuptake inhibitors, tricyclic antidepressants, sildenafil).
  • Reported cancer-related fibromyalgia or neuropathic pain conditions
  • Have a medical contraindication to, or prior serious adverse events from, cannabis or brownie ingredients (e.g., food sensitivities to gluten/wheat, chocolate, eggs)
  • Consume the equivalent of >2 cups of coffee/day (to reduce variability related to metabolic interactions with caffeine)
  • Have any of the following: uncontrolled hypertension (i.e., systolic >140 mm Hg and/or diastolic >90 mm Hg on three separate occasions; systolic >170 or diastolic >110 on any occasion), liver function tests >3 times normal, blood urea Nitrogen and Creatinine outside normal range
  • Have a physical limitation that will interfere with completing study tasks
  • Have child-bearing potential (women)

研究组 & 干预措施

Cannabis (up to three doses)

Experimental

Brownies containing a dose of cannabis

干预措施: Cannabis (up to three doses) (Drug)

结局指标

主要结局

Self/Observer Ratings - POMS

时间窗: pre-drug and 1, 2, 3, and 5.5 hours post-drug administration

Profile of Mood States (POMS) short form - using a five-point scale ranging from "not at all" to "extremely."

Self/Observer Ratings - CADSS

时间窗: pre-drug and 1, 2, 3, and 5.5 hours post-drug administration

Clinician Administered Dissociative Symptoms Scale (CADSS)-

Balance Tests - Timed Up and Go

时间窗: pre-drug and 1, 2, 3, and 5.5 hours post-drug administration

The Timed Up \& Go Test- Timing commences on the command 'go' and stops when the subject's back is positioned against the back of the chair after sitting down.

Balance Tests - 30 sec chair-stand

时间窗: pre-drug and 1, 2, 3, and 5.5 hours post-drug administration

The 30-Second Chair-Stand Test- the number of times the patient comes to a full standing position in 30 seconds.

Vital Signs - Respiration

时间窗: pre-drug and 1, 2, 3, and 5.5 hours post-drug administration

respiration rate (breaths per minute)

Vital Signs - Blood Pressure

时间窗: pre-drug and 1, 2, 3, and 5.5 hours post-drug administration

systolic/diastolic blood pressure (mmHg)

Self/Observer Ratings - Pain

时间窗: pre-drug and 1, 2, 3, and 5.5 hours post-drug administration

Visual Analog Scales (making a handwritten mark on a 10-cm line that represents a continuum between "no pain" and "worst pain")

Vital Signs - Pulse

时间窗: pre-drug and 1, 2, 3, and 5.5 hours post-drug administration

pulse (beats per minute)

Self/Observer Ratings - Side Effects

时间窗: pre-drug and 1, 2, 3, and 5.5 hours post-drug administration

Side Effects Ratings

Self/Observer Ratings - PROMIS

时间窗: pre-drug and 1, 2, 3, and 5.5 hours post-drug administration

Patient Reported Outcomes Measurements Information System (PROMIS) Cognitive Function short form v2

Balance Tests - Four-Stage

时间窗: pre-drug and 1, 2, 3, and 5.5 hours post-drug administration

The Four-Stage Balance Test- When the patient is steady, let go, and time how long they can maintain the position, but remain ready to assist the patient if they should lose their balance.

次要结局

  • Cognitive Function Tests - Flanker(pre-drug and 3 hours post-drug administration)
  • Cognitive Function Tests - Picture Sequence(pre-drug and 3 hours post-drug administration)
  • Cognitive Function Tests - Sorting(pre-drug and 3 hours post-drug administration)
  • Cognitive Function Tests - Vocab(pre-drug and 3 hours post-drug administration)
  • Cognitive Function Tests - Oral Reading(pre-drug and 3 hours post-drug administration)
  • Cognitive Function Tests - Card Sort(pre-drug and 3 hours post-drug administration)
  • Cognitive Function Tests - pattern processing(pre-drug and 3 hours post-drug administration)
  • Cognitive Function Tests - Auditory learning(pre-drug and 3 hours post-drug administration)
  • Cognitive Function Tests - Oral symbol(pre-drug and 3 hours post-drug administration)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验